Janssen-Cilag International NV Release: Phase 3 Data Highlight Benefits Of Using VELCADE® Within Frontline Treatment Of Mantle Cell Lymphoma, With Results Showing Significantly Longer Progression-Free Survival Compared To Standard Of Care
6/2/2014 9:28:52 AM
BEERSE, Belgium--(BUSINESS WIRE)--NOTE: this press release relates to ASCO congress abstract #8500. Janssen-Cilag International NV today announced that data from a Phase 3 study highlighted that treating patients with newly-diagnosed Mantle Cell Lymphoma (a rare blood cancer) with a treatment combination including VELCADE® (bortezomib) in the frontline setting offers significant improvements in progression-free survival (PFS) and a range of secondary endpoints, compared to a current standard of care.
Help employers find you! Check out all the jobs and post your resume.
comments powered by